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membrane for guided bone regeneration around dental implants
Abstract
OBJECTIVES: The use of barrier membranes in guided bone regeneration (GBR) procedures for the
treatment of alveolar bone defects is common practice. The objective of this study was to test whether a
synthetic bioresorbable polyethylene glycol (PEG) hydrogel membrane could result in a similar amount
of vertical bone fill as a standard collagen membrane, both combined with a membrane supporting
material. MATERIAL AND METHODS: The study enrolled 37 patients requiring implant treatment
with an expected osseous defect in the posterior maxilla or mandible. After raising a mucoperiosteal
flap, the implant sites were prepared and dental implants placed. The defect height was then measured
and defects <3 mm were excluded from the study. Defects were grafted with bovine bone mineral and
randomly covered with either a collagen membrane (control group, 18 patients) or a PEG hydrogel
membrane (test group, 19 patients), which is applied as a liquid. After a healing period of 6 months,
surgical re-entry was performed and the change in vertical bone height from baseline evaluated.
RESULTS: Well-vascularized hard tissue was apparent at all sites and the regenerated bone was similar
to the surrounding native bone. Mean vertical defect fill after 6 months was 5.63+/-1.84 mm at test sites
and 4.25+/-1.16 mm at control sites, and the mean defect fills were 94.9% and 96.4% at test and control
sites, respectively. More soft tissue complications were observed with the PEG membrane (e.g., delayed
or incomplete wound healing) but all sites recovered uneventfully. CONCLUSIONS: The new PEG
hydrogel membrane was as successful as a standard collagen membrane in the treatment of bony
dehiscence defects around dental implants with simplified clinical handling.
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Abstract 
Objectives 
The use of barrier membranes in guided bone regeneration (GBR) procedures for 
the treatment of alveolar bone defects is common practice. The objective of this 
study was to test whether a synthetic bioresorbable polyethylene-glycol (PEG) 
hydrogel membrane could result in a similar amount of vertical bone fill as a 
standard collagen membrane, both combined with a membrane supporting material. 
Materials and Methods 
The study enrolled 37 patients requiring implant treatment with an expected osseous 
defect in the posterior maxilla or mandible. After raising a mucoperiosteal flap, the 
implant sites were prepared and dental implants placed. The defect height was then 
measured, and defects < 3 mm were excluded from the study. Defects were grafted 
with bovine bone mineral and randomly covered with either a collagen membrane 
(control group, 18 patients) or a PEG hydrogel membrane (test group, 19 patients), 
which is applied as a liquid. After a healing period of 6 months, surgical re-entry was 
performed and the change in vertical bone height from baseline evaluated. 
Results 
Well vascularized hard tissue was apparent at all sites, and the regenerated bone 
was similar to the surrounding native bone. Mean vertical defect fill after 6 months 
was 5.63 ± 1.84mm at test sites and 4.25 ± 1.16mm at control sites, and the mean 
defect fill was 94.9% and 96.4% at test and control sites, respectively. More soft 
tissue complications were observed with the PEG membrane (e.g. delayed or 
incomplete wound healing), but all sites recovered uneventfully. 
Conclusions 
The new PEG hydrogel membrane was as successful as a standard collagen 
membrane in the treatment of bony dehiscence defects around dental implants, with 
simplified clinical handling. 
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Introduction 
The method of guided bone regeneration (GBR) is most commonly used in clinical 
situations for the treatment of limited alveolar bone defects in the jaws. It is based on 
the concept of using a barrier to create a space into which the cells originating from 
bone tissue can grow without migration or interference of the faster proliferating cells 
of the connective or soft tissue (Gottlow et al. 1984; Nyman & Lang 1994). 
The tool used to generate this is a cell occlusive membrane, which can be 
manufactured from different natural or synthetic polymers. Nowadays, bio-
degradable membranes made of collagen have become the standard of care in 
many clinical situations (Zitzmann et al. 1997; Hämmerle et al. 1998; Jung et al. 
2003; Moses et al. 2005). 
Common to all currently used membranes is the fact that their fabrication is 
completed before they are delivered for patient use. Consequently, they are made 
available in standard sizes and forms and need to be adapted to the patientʼs 
individual situation. The availability of a synthetic and resorbable membrane that 
could be directly custom made intra-operatively for an individual defect would 
therefore represent an improvement for future GBR procedures. 
Experimental studies have introduced a newly developed synthetic hydrogel made of 
polyethylene glycol (PEG) for use in bone regeneration therapy (Lutolf et al. 2003; 
Jung et al. 2006; Wechsler et al. 2007). PEG has been shown to be highly 
biocompatible and was investigated in other medicine disciplines, e.g. as a 
sprayable adhesion barrier (Mettler et al. 2003; Vaage et al. 1997). Several 
preclinical studies with different animal models have been conducted to evaluate the 
possibilities and limitations of this PEG material for its use as a barrier membrane or 
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matrix in GBR procedure (Jung et al. 2006; Wechsler et al. 2007; Thoma et al.) The 
promising results from these experimental studies have led to investigations of the 
efficacy and the feasibility of the PEG membrane for the first time in clinical 
situations. 
The primary aim of the present study was to test whether a synthetic and 
biodegradable PEG membrane could result in a similar amount of vertical bone fill as 
a standard collagen membrane, both combined with a membrane supporting 
material. 
 
Materials and Methods 
The present study was a prospective, controlled, randomized, clinical investigation. 
All procedures and materials were approved by the local ethical committee. Informed 
consent was obtained from all patients. 
 
Patients 
The study recruited 37 male or female patients in need of implant treatment in at 
least one site with an expected osseous defect in the posterior mandible or maxilla. 
All patients were in good general health and underwent comprehensive dental care. 
Enrolled patients complied with all of the inclusion and exclusion criteria. Two of the 
inclusion criteria, such as primary stability of the dental implant and osseous defect ≥ 
3 mm in vertical dimension could only be evaluated on the day of surgery. If two or 
more sites were still available fulfilling the defect criterion, one was selected by 
throwing a die. The selected site was assigned to a treatment according to the 
randomization envelope. 
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In the event that a patient was found to be ineligible for the study at the time of 
surgery, an alternative treatment following good clinical standards was offered to the 
patient. 
 
PEG biodegradable hydrogel membrane 
The investigational device is a synthetic biodegradable barrier membrane (Institut 
Straumann AG, Basel, Switzerland) composed of two multifunctional PEG 
molecules. The membrane material is applied as liquid and forms a hydrogel by a 
cross-linking reaction within a few seconds after application. The membrane is 
degraded hydrolytically during the healing period.  
The PEG components and corresponding buffers are supplied in four separate 
syringes and have to be mixed immediately before use. 
 
Surgical procedure 
The implant placement was performed either as a delayed (between 6 weeks and 6 
months after extraction) or a late procedure (more than 6 months after extraction). 
Before surgery the patients received antibiotics (2 x 750 mg Clamoxyl®; 
GlaxoSmithKline AG, Münchenbuchsee, Switzerland) and analgesics/antiphlogistics 
(500 mg Mefenacid®; Streuli Pharma AG, Uznach, Switzerland). Surgery was 
performed under local anesthetic. The incision was placed at the mid-crest, with 
releasing incisions if necessary, and a mucoperiosteal flap was raised. The implant 
site was prepared according to current standard Straumann instructions and a 
Straumann SLA solid screw implant (Institut Straumann AG, Basel, Switzerland) was 
inserted. 
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Immediately after implantation, initial implant stability was assessed by hand testing. 
If any implant lacked primary stability at this assessment, the patient was excluded 
from further participation in the study. 
The osseous defect of eligible sites was determined after implant placement with the 
help of a calibrated periodontal probe. If the defect height was < 3 mm, the patient 
was excluded from the study. If the defect height was ≥ 3 mm the site was assigned 
to a treatment according to the randomization envelope. 
 
Measurement of defect size 
• Defect height (mm) measured from the SLA surface border of the implant to the 
first bone-to-implant contact (BIC; Fig. 1a). 
• Defect width (mm) measured from the mesial to the distal bone crests (Fig. 1b). 
• Defect depth (mm) measured from the bone crest to the implant surface in a 
direction perpendicular to the long axis of the implant (Fig. 1c). 
• Infrabony defect height (mm) measured from the bone crest to the first BIC (Fig. 
1d). 
 
Augmentation procedure 
Osseous defects around implants were grafted with a natural bone mineral of bovine 
origin (BioOss® Spongiosa Granules, particle size 0.25 – 1.0 mm; Geistlich Pharma 
AG, Wolhusen, Switzerland). The defect was filled with the bone substitute without 
being overfilled. The natural bone mineral was used alone. Horizontal thickness after 
augmentation procedure was assessed; this value was 0 before the GBR procedure 
(Fig. 1e). 
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Afterwards the xenogenic bone substitute was covered according to the 
randomization with either test or control membrane. 
• Test group (PEG Membrane): The filled defect was covered with the PEG 
membrane. The prepared gel was applied directly over the bone substitute using 
the dental tip of the static mixer. After the in situ gelation the membrane had to 
overlap the walls of the defect by at least 2 mm. The thickness was 
approximately 1 mm. No fixation was needed as the gel adheres to the 
surrounding tissues (Fig. 2). 
• Control group (BioGide® Membrane; Geistlich Pharma AG, Wolhusen, 
Switzerland)): The filled defect was covered with a standard collagen membrane. 
The size of the membrane was adapted using scissors according to the exposed 
bone defect. The membrane overlapped the walls of the defect by at least 2 mm 
to allow complete bone contact and to prevent gingival connective tissue invasion 
below the material. The membrane was fixed by resorbable pins made of 
polylactic acid (Resor Pin®; Geistlich AG, Wolhusen, Switzerland) to avoid 
membrane displacement due to loading or mobilization. 
 
For test and control sites, the time taken for extraoral membrane preparation and for 
surgical application was recorded. Extraoral membrane preparation included 
opening of package and mixing of PEG membrane components, and cutting the 
collagen membrane with scissors. In the test group, surgical application included 
application and gelation of the PEG membrane. In the control group, application 
consisted of adapting and fixing the collagen membrane. 
Wound closure 
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Periosteal releasing incisions were used to allow tension-free adaptation of the 
mucoperiosteal flaps. Healing was attempted with the implants in a submerged 
position (except for two test sites with non-submerged healing). The sutures used 
were ePTFE non-absorbable monofilament sutures (Gore-Tex® suture; Gore, 
Flagstaff, AZ, USA). 
 
Postoperative treatment 
The patients were instructed to rinse twice daily with an aqueous solution of 0.2% 
chlorhexidine and to continue the antibiotic regimen for 5 days (750 mg Clamoxyl®, 
three times a day). In addition, analgesics (500 mg Mefenacid) were prescribed for 
the next 2 days according to individual needs. Patients were also instructed to refrain 
from mechanical plaque removal in the area of implantation for 1 week. The sutures 
were removed 7 to 10 days following implantation.  
 
Re-entry 
Six months later, a re-entry surgery was performed to assess the result of the 
attempted regeneration. Mucoperiosteal flaps were reflected to allow for exact 
evaluation. The same clinical measurements assessed at baseline were again 
recorded (Fig. 1a to 1d). To assess horizontal thickness after augmentation 
procedure (Fig. 1e) a special measuring abutment was placed on the implant. Cover 
screws were replaced by healing abutments. Subsequently, the flaps were adjusted 
to fit around the neck of the healing abutment and sutured. One week later, the 
sutures were removed.  
Statistical evaluation 
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The change in vertical bone level after 6 months was the primary variable for this 
study. The power-analysis showed that with a minimum of 17 patients per group 
(total of 34 patients) it will be possible to detect a difference of 1mm between the test 
and control group with a standard deviation σ = 1 and a significance level of α=0.05 
with a power of 80%. To protect from possible drop-outs the sample size was 
increased by 10% resulting in 18 patients per group (total of 36 patients). The 
secondary variables related to bone regeneration and consisted of measurements of 
the defect width, defect depth, infrabony defect and the horizontal thickness of the 
augmented bone. Data were reported using means and standard deviations (SDs). 
The 2-sided t-test was selected to detect differences between the test and the 
control sites. The level of statistical significance was set at p ≤ 0.05. 
Soft tissue healing for both groups was clinically assessed and descriptively listed. A 
comparison of time taken for the extraoral preparation and the intraoral application of 
the two membranes was made. 
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Results 
Patients 
Thirty-seven patients were enrolled and entered in the trial; 19 were randomized to 
test group (PEG Hydrogel) and 18 to the control group (collagen membrane). The 
mean age was 48 years (range 32-72 years) in the test group and 54 years (range 
23-80 years) in the control group.  
 
Clinical observations at baseline 
Both treatment groups were homogeneous with regard to the baseline values of the 
quantitative variables measured, with the exception of the defect height. At baseline, 
mean defect height was 5.95 ± 1.90 mm in the test group and 4.50 ± 1.54 mm in the 
control group, showing a statistically significant difference (p = 0.016). 
 
Healing period, soft tissue 
After an observation period of 6 months no evidence of serious adverse local or 
systemic effects was observed in any of the groups. 
During the healing period 9 patients treated with test membrane and 6 with the 
control membrane complained of mild to moderate adverse events. Of these, 2 
patients in each group complained about pain or discomfort during the initial healing 
period. In the test group 6 sites with a delayed wound healing and/or a remaining 
dehiscence on top of the cover screw were observed (Fig. 3). No special care was 
needed for these sites. In another 3 sites in the test group the wound healing was 
primarily uneventful. However, after 5 to 7 weeks these sites showed a slight buccal 
dehiscence defect with an exposure of the implant shoulder (Fig. 4). Local 
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disinfection (rinsing with 0.2% chlorhexidine) was performed. All sites recovered 
even though dehiscence remained until re-entry surgery. In the control group 4 sites 
with delayed or incomplete wound healing were observed (Fig. 5). All of them 
recovered uneventfully. 
 
Clinical observations at re-entry, bone volume and quality 
After a healing period of 6 months, a re-entry operation was performed for abutment 
connection and to measure the residual defects. At this time point, all implants were 
stable. 
The quality of the newly formed bone varied from very dense bone to more soft 
bone. In cases with dense bone almost no graft particles could still be seen. The 
regenerated bone was very similar to the surrounding native bone. The majority of 
the cases showed a bone quality where the graft particles were still recognizable on 
the surface of the regenerated area but embedded in newly formed bone. (Fig 6) 
 
Sufficient bone volume and quality was observed at all sites, even where soft tissue 
healing was delayed or incomplete.  
In all sites the defect heights had decreased. At the test and the control sites a 
vertical defect fill of 5.63 ± 1.84 mm and 4.25 ± 1.16 mm, respectively, was observed 
(Fig 7a). This difference of vertical defect fill between test and control membrane 
was statistically significant. However, the percentage of vertical bone defect filling 
after 6 months did not reveal a statistically significant difference between the two 
groups (Fig 7b). At the test and control sites, the calculated vertical defect fill was 
94.9% and 96.4%, respectively. 
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Regarding change in defect depth (Fig 8a) and defect width (Fig 8b), no statistically 
significant differences between the two groups were observed. 
 
Time for membrane application 
For test and control sites, the time taken for extraoral membrane preparation and for 
surgical application was recorded. The extraoral preparation time was slightly lower 
for the PEG hydrogel membrane, and the intraoral application time was significantly 
lower (p < 0.001; Table 1). 
 
Discussion 
The present study demonstrated that a synthetic in situ forming PEG membrane can 
successfully be used as a biodegradable barrier membrane for guided bone 
regeneration in humans. This was documented by a similar amount of defect 
resolution compared to defects treated with a standard collagen membrane. 
This randomized controlled clinical study was designed in a similar way to a previous 
human study evaluating the effect of rhBMP-2 in dehiscence type bone defects 
around dental implants (Jung et al. 2003). Both studies reported similar initial defect 
heights ranging from 4.5 to 6.0 mm in the present study and from 5.8 to 7.0 mm in 
the previous study. In addition, the favorable data of the present study regarding 
mean vertical bone fill obtained at the control (96.4%) and at the test sites (94.9%) 
correspond well with previous clinical studies using resorbable and non-resorbable 
membranes. These clinical studies reported mean vertical defect resolutions of 92% 
(Zitzmann et al. 1997), 86% (Hämmerle & Lang 2001) and 91% (Jung et al. 2003) 
using the same collagen membrane and the same xenogenic bone substitute 
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mineral as the control sites in the present study. These comparable values reveal 
that the PEG membrane was at least as effective in treating dehiscence type bone 
defects around dental implants as a standard collagen membrane. This was also 
documented by the fact that the changes in defect height in mm were statistically 
significantly higher in the test group (5.63 mm) compared to the control group (4.25 
mm). However, it has to be taken into account that the initial defect height was 
slightly higher in the test group compared to the control group. Hence, the 
normalized data (% changes against baseline) no longer revealed any statistically 
significant difference between the test and the control group. Regarding the changes 
in defect depth, the control group revealed a higher standard deviation than the test 
group, although no difference could be detected in the mean values. It might be 
speculated that the PEG membrane revealed a more consistent stability of the 
augmented volume. Therefore, the soft tissue pressure of the surrounding mucosa 
might not have the same negative influence to the regeneration volume for the PEG 
membrane compared to the collagen membrane. 
The majority of the cases in both groups showed a bone quality where the graft 
particles were still recognizable on the surface of the new tissue. This is in line with 
other clinical studies treating bone defects simultaneously with dental implant 
placement reporting similar clinical observations (Zitzmann et al. 1997; Jung et al. 
2003). On a histological level one study stated, that the individual particles of the 
xenogenic bone substitute mineral were clearly identifiable and they were found to 
be surrounded by varying amounts of newly formed bone, osteoid and bone marrow 
(Jung et al. 2003). This could possible explain that some reentry sites in the present 
study revealed a more softer bone than others. 
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Future developments of GBR membranes can either be related to increasing the 
safety and predictability of the membranes and/or simplifying the clinical handling. 
Collagen membranes are the most often used resorbable membranes and have 
been extensively tested in human and animal studies (Zitzmann et al. 2001; Jung et 
al. 2003; Moses et al. 2005). However, collagen is derived from animal materials and 
carries the potential risk of immunogenic reactions and transmission of animal 
derived pathogens (Schwarztmann 2000). In order to overcome these difficulties a 
synthetic membrane made of polyethylene glycol (PEG) has been developed. The 
PEG material has been successfully investigated in several preclinical studies for 
use as a matrix system to release bioactive molecules (Lutolf et al. 2003; Jung et al. 
2007a, Jung et al. 2007b) and as a GBR membrane (Jung et al. 2006). In addition to 
these indications PEG is presently used in other medical disciplines. The safety and 
effectiveness of a sprayable PEG material used as a barrier system in laparoscopic 
surgery has been assessed in a randomized, prospective, controlled, clinical trial 
(Mettler et al. 2004). It was demonstrated that the PEG material was safe and well 
tolerated, with no adverse effects attributed to the material and no patients in whom 
it could not be applied. In the present study no serious adverse events were reported 
during the 6-month study period. However, 9 patients treated with PEG hydrogel and 
6 with collagen membrane complained of mild to moderate adverse events ranging 
from pain and discomfort to soft tissue dehiscence.  
The clinical evaluation of the soft tissue coverage at the time of suture removal 
revealed 6 instances of small to moderate soft tissue dehiscence at the test sites 
(31%) and 4 of moderate soft tissue dehiscence at the control sites (22%). All had an 
uneventful recovery without removing the membrane. However, only one site per 
group healed completely whereas the others remained with an exposure of the cover 
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screw. At the test sites the exposures were generally very small (< 1 mm), whereas 
at the control sites almost the entire cover screw was exposed after 30 days. This is 
in agreement with another clinical study comparing two different collagen 
membranes with an ePTFE membrane (Moses et al. 2005). The authors reported 
32.1% wound dehiscence at the time of suture removal using the same collagen 
membrane as in the present study. Soft tissue healing over these exposed barriers 
were noticed only in one out of 9 patients. Regarding the amount of soft tissue 
complications, a previous study evaluated the same resorbable collagen membrane 
and a non-resorbable ePTFE membrane for GBR at dehiscence type bone defects 
(Zitzmann et al. 1997). The authors reported a total of incomplete wound closure 
after 7-10 days of 16% for the collagen membrane and of 22% for the ePTFE 
membrane. Another study investigated a newly developed cross-linked collagen 
membrane (Friedman et al. 2002). In this study only 5 out of 14 sites healed 
uneventfully. In 9 patients (64%) soft tissue dehiscence occurred within the first 14 
postoperative days. However, within the following 4 weeks the healing by secondary 
epithelialization was completed in all 9 exposed sites. The reasons for these 
generally high values of soft tissue complications remain unclear. In the present 
study one reason for the relatively high numbers of complications might be that the 
patients have been treated in the post-graduate clinic with less experienced 
surgeons. An additional reason may be that very small dehiscence with diameters < 
1 mm that recovered after 1-2 weeks have also been recorded as adverse events. In 
contrast to the control sites, 3 out of 19 test sites revealed a late soft tissue 
dehiscence. These complications occurred mainly in the posterior mandible with very 
little or no keratinized mucosa exposing the buccal implant shoulder. It is unclear 
whether this delayed dehiscense after 5-7 weeks is attributed to the lack of 
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keratinized mucosa and the perforating implant shoulder or to the PEG membrane 
itself. After the implant shoulder was exposed no further complications occurred. It 
would be interesting to further evaluate the soft tissue integration properties of the 
PEG material.  
An additional development in future GBR procedures may be a simplification of the 
clinical handling. Common to all presently used membranes is the fact that their 
fabrication is completed before they are delivered for patient use. Consequently, they 
are made available in standard sizes and forms and need to be adapted to the 
patientʼs individual situation. In contrast to the control membrane, the presently used 
PEG membrane can be custom made for an individual defect directly intra-
operatively. This allowed a reduction of the intraoral application time by more than 3 
times compared to the control membranes. There are no other studies available 
describing the time needed for GBR procedures. 
It can be concluded that the in situ formed PEG membrane could be successfully 
used to treat bony dehiscence defects around dental implants with similar amounts 
of defect resolutions as achieved with a standard collagen membrane. The test 
membrane revealed more soft tissue complications than the collagen membrane. 
The PEG membrane showed a favorable and simplified clinical handling as well as a 
decreased intraoral application time. 
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Figure Legends 
 
Figure 1: a) defect height from SLA surface border to first BIC; b) defect width from 
mesial to distal bone crests; c) defect depth from bone crest to implant surface; d) 
defect height from bone crest to first BIC; e) horizontal thickness after filling with 
natural bone mineral 
 
Figure 2: In situ application of PEG hydrogel membrane 
 
Figure 3: Remaining dehiscence during the healing period observed in 6 sites in the 
test group 
 
Figure 4: Buccal dehiscence with exposure of implant shoulder observed in three 
sites in the test group after 5-7 weeks 
 
Figure 5: Delayed/incomplete wound healing observed in 4 sites in the control group 
 
Figure 6: Graft particles on surface and embedded in newly formed bone 
 
Figure 7: a) Change in defect height (mm); b) vertical defect bone fill (%) 
 
Figure 8: a) Change in defect depth (mm); b) change in defect width (mm) 
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Figure 7:  
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Figure 8:  
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Table 1: Time taken for extraoral preparation and intraoral application of membranes 
 Patients 
(N) 
Mean (SD) in sec p value for differences 
between treatment groups 
Extraoral    
PEG Hydrogel 19 96.79 (39.23) 
Collagen 18 124.83 ( 63.95) 
 
0.115 
Intraoral    
PEG Hydrogel 19 61.00 (25.54) 
Collagen 18 194.83 (122.50) 
 
0.000 
 
